MEDFAR Acquires AlloMia to Expand AI-Powered Automation Across Healthcare Practices
MEDFAR, the Canadian healthcare technology company behind the MYLE electronic medical record (EMR) platform, has acquired AI conversational agent developer AlloMia, marking its second AI technology acquisition in under two years. AlloMia’s AI voice agent answers patient calls around the clock, manages requests, and books appointments directly into clinic schedules. In recently onboarded pilot clinics, it independently handles approximately 50% of calls from start to finish. The acquisition adds a fourth AI capability to MYLE, alongside AI Scribe, AI Form-Filling, and AI Indexing, extending automation across clinical documentation, administrative workflows, and patient communication. The AlloMia team has joined MEDFAR, and the solution is now available to all MYLE clinics. It also integrates with Plexia and Medgen EMRs, extending its reach beyond the MYLE ecosystem.
Amgen Canada Launches Uplizna for Generalized Myasthenia Gravis
Amgen Canada has launched Uplizna (inebilizumab) as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who test positive for anti-AChR or anti-MuSK antibodies. The CD19-targeting therapy addresses B cells involved in the underlying disease process and is administered twice yearly for maintenance following two initial loading doses. Health Canada’s authorization is supported by the Phase 3 MINT trial, which included both antibody-positive patient groups and a structured steroid-tapering protocol. By Week 26, 87.4% of Uplizna-treated patients had reduced their daily prednisone dose to 5 mg or less. The launch expands Uplizna’s Canadian use beyond neuromyelitis optica spectrum disorder and IgG4-related disease. Amgen’s Entrust Rare Patient Support Program will also provide eligible patients with personalized assistance throughout treatment.
Boehringer Ingelheim’s Jascayd Receives Health Canada Authorization for IPF and PPF
Boehringer Ingelheim Canada has received Health Canada authorization for Jascayd (nerandomilast) for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), introducing Canada’s first authorized PDE4B inhibitor for these indications. The authorization is supported by the Phase III FIBRONEER-IPF and FIBRONEER-ILD trials, which met their primary endpoints by demonstrating slower lung function decline, measured by forced vital capacity (FVC), versus placebo at Week 52. Although key secondary endpoints were not met in either trial, both studies showed a numerical reduction in mortality, reaching nominal statistical significance in FIBRONEER-ILD. Nerandomilast also demonstrated a favorable safety profile without requiring liver monitoring. The authorization adds a new treatment option for progressive fibrotic lung diseases, including IPF, which affects an estimated 17,000-plus Canadians.
Sanofi Secures pCPA Letter of Intent for Dupixent Across Four Additional Indications in Canada
Sanofi has signed a Letter of Intent (LOI) with Canada’s pan-Canadian Pharmaceutical Alliance (pCPA) for Dupixent (dupilumab) across four additional indications: pediatric atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The agreement advances reimbursement discussions for eligible patients with moderate-to-severe atopic dermatitis and adults with prurigo nodularis whose conditions are inadequately controlled with prescription topical therapies. In respiratory diseases, it covers adults with COPD and elevated blood eosinophils despite standard inhaled treatment, as well as patients with severe CRSwNP inadequately controlled by systemic corticosteroids and/or surgery. Sanofi will continue working with public payers to support patient access, moving Dupixent closer to potential public reimbursement across these four indications in Canada.
